Roche has licensed Simcere Zaiming’s preclinical trispecific antibody SIM0660, paying $75 million (€65 million) upfront in a ...
Novartis’ remibrutinib has beaten teriflunomide in two Phase 3 trials in relapsing multiple sclerosis (MS), adding another ...
Swiss biotech NovaGo Therapeutics has raised CHF 24 million ($30 million/€25.5 million) in a Series B round to advance its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results